Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MultiCell Technologies has reported that it is advancing its colorectal cancer therapeutic candidate to preclinical development status.
Subscribe to our email newsletter
MCT-475 is indicated as a prospective treatment for metastatic colorectal cancer which is intended to be co-administered with MCT-465, a Toll-like Receptor (TLR) agonist.
“Previously we demonstrated that co-administration of MCT-465 with our patent pending antigen-presenting immunoglobulin therapeutic IgNP prototype completely destroyed tumors, and prevented mortality and recurrence in animal models,” said Dr Stephen Chang, president and CEO of Multicell Technologies.
“MCT-475 is designed to activate the adaptive immune system to target unique structural motifs located on the surface of human metastatic colorectal cancer cells, while MCT-465 is designed to activate the innate immune system through TLR signaling. Working together, MCT-475 and MCT-465 stimulate the body's immune system to target and kill metastatic colorectal cells.”
Colorectal cancer is the third most common cancer in both men and women in the US, and remains the third leading cause of death from cancer in the US. The American Cancer Society estimates that about 145,000 new cases of colorectal cancer were reported in 2005.